Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive

Heuvel, Michiel W. van den; Bragt, Antoinetta Jacoba Maria van; Alnabawy, Ali Kafi Mohammed; Kaptein, Marc

doi:10.1016/j.contraception.2005.03.005

Cited by 285 publications

(132 citation statements)

References 11 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…151,152 Studies to date have yielded inconsistent results about how the risk of VTE with use of the ring compares with the risk with use of low-dose COCs. [153][154][155][156] Analogous to experience with the contraceptive patch, it has not been clearly demonstrated that the simplified regimen afforded by the ring results in improved medication adherence or continuation in young people. 157 A trial of 237 college students randomized to use either the ring or COC found that perfect use was greater for the ring in the first 2 months but that this was no longer statistically significant in the third month of the study.…”

Section: Contraceptive Vaginal Ringmentioning

confidence: 99%

“…161 Transdermal Contraceptive Patch 162 after publicity about increased estrogen exposure from the patch, which has been found to be 1.6 times higher than estrogen exposure with a COC. 153 The patch has undergone multiple label revisions, most recently August 22, 2012. The 2012 package insert contains a black box warning citing 5 US studies [163][164][165][166][167][168][169][170] (1 with statistically significant findings) that suggest a possible increased risk of VTE compared with a 20-to 35-μg COC, with odds ratios of 1.2 to 2.2.…”

Section: Pediatrics Volume 134 Number 4 October 2014 E1267mentioning

confidence: 99%

See 1 more Smart Citation

Contraception for Adolescents

Ott

Sucato²

2014

Pediatrics

245

133

View full text Add to dashboard Cite

A working knowledge of contraception will assist the pediatrician in both sexual health promotion as well as treatment of common adolescent gynecologic problems. Best practices in adolescent anticipatory guidance and screening include a sexual health history, screening for pregnancy and sexually transmitted infections, counseling, and if indicated, providing access to contraceptives. Pediatricians’ long-term relationships with adolescents and families allow them to help promote healthy sexual decision-making, including abstinence and contraceptive use. Additionally, medical indications for contraception, such as acne, dysmenorrhea, and heavy menstrual bleeding, are frequently uncovered during adolescent visits. This technical report provides an evidence base for the accompanying policy statement and addresses key aspects of adolescent contraceptive use, including the following: (1) sexual history taking, confidentiality, and counseling; (2) adolescent data on the use and side effects of newer contraceptive methods; (3) new data on older contraceptive methods; and (4) evidence supporting the use of contraceptives in adolescent patients with complex medical conditions.

show abstract

Section: Contraceptive Vaginal Ringmentioning

confidence: 99%

Section: Pediatrics Volume 134 Number 4 October 2014 E1267mentioning

confidence: 99%

Contraception for Adolescents

Ott

Sucato²

2014

Pediatrics

245

133

View full text Add to dashboard Cite

show abstract

“…Typical use failure rates are similar to those of COCs at 9%. 32 The FDA has identified increased estrogen exposure (1.6 times higher than with a low-dose COC 111 ) and a potential increased risk of venous thromboembolism with the patch 112,113 (see accompanying technical report for more complete discussion).…”

Section: Contraceptive Vaginal Ringmentioning

confidence: 99%

Contraception for Adolescents

Braverman¹,

Adelman²,

Alderman³

et al. 2014

Pediatrics

311

107

View full text Add to dashboard Cite

Contraception is a pillar in reducing adolescent pregnancy rates. The American Academy of Pediatrics recommends that pediatricians develop a working knowledge of contraception to help adolescents reduce risks of and negative health consequences related to unintended pregnancy. Over the past 10 years, a number of new contraceptive methods have become available to adolescents, newer guidance has been issued on existing contraceptive methods, and the evidence base for contraception for special populations (adolescents who have disabilities, are obese, are recipients of solid organ transplants, or are HIV infected) has expanded. The Academy has addressed contraception since 1980, and this policy statement updates the 2007 statement on contraception and adolescents. It provides the pediatrician with a description and rationale for best practices in counseling and prescribing contraception for adolescents. It is supported by an accompanying technical report.

show abstract

“…Prema podacima proizvođača, efikasnost transdermalnih flastera za KHK se generalno ne razlikuje od kombinovanih oralnih kontraceptiva, ali može biti niža kod žena sa telesnom masom većom od 90 kg. Farmakokinetičke studije kod zdravih dobrovoljaca koje su objavljene 2005. godine pokazale su da je relativna biološka raspoloživost etinilestradiola iz OrthoEvra  transdermalnog flastera veća za 55%, mada je maksimalna koncentracija u plazmi (C max ) značajno niža (za 35%) u poređenju sa kombinovanim oralnim kontraceptivom norgestimat 250 mcg + etinilestradiol 35 mcg [27,28,30]. Na osnovu zapažanja o značajno većoj raspoloživosti etinilestradiola, tokom 2008. godine Američka uprava za hranu i lekove (US Food and Drug Administration, FDA) izdala je upozorenje o gotovo dvostruko većem riziku od venske tromboembolije (VTE) kod korisnica OrthoEvra Glavni pristup u razvoju novih transdermalnih flastera za KHK je redukcija doze estrogena etinilestradiola u cilju smanjenja rizika od neželjenih efekata i iritacije na mestu primene, uz nepromenjenu efikasnost u zaštiti od trudnoće.…”

Section: Transdermalni Flasteri Za Khkunclassified

Pharmaceutical-technological aspects of therapeutic systems for hormonal contraception

Djekić¹,

Primorac²

2016

Arh farmaciju

View full text Add to dashboard Cite

Univerzitet u Beogradu -Farmaceutski fakultet, Katedra za farmaceutsku tehnologiju i kozmetologiju, Vojvode Stepe 450, 11221 Beograd, Srbija Kratak sadržajUpotreba terapijskih sistema za hormonsku kontracepciju (TSHK) predstavlja značajan alternativni vid sprečavanja neplanirane trudnoće u odnosu na primenu hormonskih kontraceptiva per os, pri čemu se otklanja rizik od gastrointestinalnih neželjenih reakcija, omogućava smanjenje terapijske doze, učestalosti primene i sistemskih neželjenih dejstava i povećava nivo adherence. Do sada su razvijeni terapijski sistemi tipa transdermalnih flastera, subdermalnih (supkutanih) implanata, vaginalnih prstenova i intrauternih terapijskih (dostavnih) sistema (IUS) za hormonsku kontracepciju progestinima (progesteron, levonorgestrel, etonogestrel, nestoron) ili kombinacijama progestina i estrogena (norelgestormin + etinilestradiol, gestoden + etinilestradiol, etonogestrel + etinilestradiol, levonorgestrel + etinilestradiol, nestoron + etinilestradiol, nestoron + estradiol). U radu su prikazane glavne karakteristike navedenih tipova TSHK, kao i specifičnosti farmaceutskih proizvoda ove vrste u pogledu sastava i primene. Opisani su glavni mehanizmi za postizanje kontrolisanog produženog oslobađanja hormona i efikasnost za isporuku aktivnih supstanci kod različitih TSHK. Predstavljeni su najznačajniji savremeni pristupi u dizajnu terapijskih sistema ove vrste sa ciljem da se pojednostavi njihova primena, poboljša podnošljivost, prihvatljivost i terapijska efikasnost, a ukazano je i na mogućnost korišćenja novih tehnologija u razvoju terapijskih sistema za višenamensku prevenciju začeća i infekcije virusom humane imunodeficijencije (human immunodeficiency virus, HIV).Ključne reči: terapijski sistemi za hormonsku kontracepciju; transdermalni flaster; subdermalni (supkutani) implant; vaginalni prsten; intrauterini terapijski (dostavni) sistem; progestini; estrogeni; kontrolisano/produženo oslobađanje; tehnologije za višenamensku prevenciju.

show abstract

Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive

Cited by 285 publications

References 11 publications

Contraception for Adolescents

Contraception for Adolescents

Contraception for Adolescents

Pharmaceutical-technological aspects of therapeutic systems for hormonal contraception

Contact Info

Product

Resources

About